Cargando…
NOTCH4 mutation as predictive biomarker for immunotherapy benefits in NRAS wildtype melanoma
BACKGROUND: NRAS wildtype melanoma accounts for approximately 80% of melanomas. Previous studies have shown that NRAS wildtype melanoma had higher response rates and better prognoses than NRAS-mutant patients following immunotherapy, while as major actors in tumor cells and tumor microenvironment (T...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9372281/ https://www.ncbi.nlm.nih.gov/pubmed/35967450 http://dx.doi.org/10.3389/fimmu.2022.894110 |